<DOC>
	<DOCNO>NCT00489710</DOCNO>
	<brief_summary>RATIONALE : Talabostat may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well talabostat work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Talabostat Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient metastatic renal cell carcinoma treat talabostat mesylate . - Determine progression-free survival patient treated drug . Secondary - Determine toxicity drug patient . - Correlate change specific cytokine level peripheral blood flow cytometry progression-free survival . OUTLINE : This nonrandomized study . Patients receive oral talabostat mesylate daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Blood sample obtain patient baseline course biomarker correlative study . Samples analyze serum cytokine chemokines T-cell subset NK cell flow cytometry . Peripheral blood lymphocyte obtain baseline course 1 future assessment gene microarray analysis .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologic diagnosis renal cell carcinoma Clinical confirmation metastatic disease require Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan The following consider nonmeasurable disease : Small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) Bone lesion Leptomeningeal disease Ascites Pleural pericardial effusion Lymphangitis cutis pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Progressed ≥ 1 multikinase inhibitor regimen ( i.e. , sorafenib tosylate sunitinib malate ) No history CNS brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.5 g/dL ( pack red blood cell transfusion within past 4 week ) ( epoetin alfa support allow ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( unless due Gilbert 's syndrome ) AST ALT ≤ 3 time ULN Creatinine &lt; 2.0 mg/dL No active serious infection No malignancy within past 5 year except basal cell nonmetastatic squamous cell skin cancer carcinoma situ cervix No comorbidity concurrent condition would interfere protocol assessment procedures No ongoing coagulopathy PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior systemic therapy recover Prior radiotherapy allow long lesion treat used ass response No prior radiotherapy &gt; 50 % bone marrow No prior radiotherapy index lesion unless clearly progressive disease within irradiated area OR measurable disease outside irradiated area</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>